WO2007036706A1 - Variantes du lantibiotique mersacidine, et leur utilisation - Google Patents

Variantes du lantibiotique mersacidine, et leur utilisation Download PDF

Info

Publication number
WO2007036706A1
WO2007036706A1 PCT/GB2006/003570 GB2006003570W WO2007036706A1 WO 2007036706 A1 WO2007036706 A1 WO 2007036706A1 GB 2006003570 W GB2006003570 W GB 2006003570W WO 2007036706 A1 WO2007036706 A1 WO 2007036706A1
Authority
WO
WIPO (PCT)
Prior art keywords
mersacidin
treatment
variant
composition
variants
Prior art date
Application number
PCT/GB2006/003570
Other languages
English (en)
Inventor
Michael John Dawson
Jesus Cortes Bargallo
Antony Nicholas Appleyard
Original Assignee
Novacta Biosystems Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Limited filed Critical Novacta Biosystems Limited
Priority to EP06794575A priority Critical patent/EP1928900A1/fr
Priority to JP2008532859A priority patent/JP2009509519A/ja
Priority to CA002623624A priority patent/CA2623624A1/fr
Publication of WO2007036706A1 publication Critical patent/WO2007036706A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Another approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., US Patent No. 3,710,795.
  • samples Prior to bioassay of the components in broth samples and fermentation concentrate, samples were fractionated using an analytical HPLC coupled to a 96 well microtitre plate fraction collector. In general, 0.2 ml of broth sample or fermentation concentrate was loaded onto the column and the components were resolved and collected as described in Table 7. The fractions in the 96 well microtitre plates were evaporated to dryness and the resulting residues were dissolved in 50 ⁇ l of methanohwater (1 :1). For each variant the resuspended residues from fractions 36 to 43 were loaded onto bioassay agar plates containing Micrococcus luteus ATCC 4698 as indicator strain. The bioassay plates containing the mersacidin variant samples were left at room temperature for 1 hour to allow diffusion of the sample into the agar prior to incubation at 30 0 C overnight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des variantes du lantibiotique mersacidine, ainsi que des procédés de production de ces variantes.
PCT/GB2006/003570 2005-09-27 2006-09-26 Variantes du lantibiotique mersacidine, et leur utilisation WO2007036706A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06794575A EP1928900A1 (fr) 2005-09-27 2006-09-26 Variantes du lantibiotique mersacidine, et leur utilisation
JP2008532859A JP2009509519A (ja) 2005-09-27 2006-09-26 ランチビオティックメルサシジンの変種およびそれらの使用
CA002623624A CA2623624A1 (fr) 2005-09-27 2006-09-26 Variantes du lantibiotique mersacidine, et leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72046405P 2005-09-27 2005-09-27
US60/720,464 2005-09-27

Publications (1)

Publication Number Publication Date
WO2007036706A1 true WO2007036706A1 (fr) 2007-04-05

Family

ID=37728346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003570 WO2007036706A1 (fr) 2005-09-27 2006-09-26 Variantes du lantibiotique mersacidine, et leur utilisation

Country Status (4)

Country Link
EP (1) EP1928900A1 (fr)
JP (1) JP2009509519A (fr)
CA (1) CA2623624A1 (fr)
WO (1) WO2007036706A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1794298A2 (fr) * 2004-03-26 2007-06-13 Novacta Biosystems Limited Production de mersacidine et ses variants dans des cellules hotes negatives de bacillus sigh et/ou mrsa
WO2009010763A1 (fr) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Utilisation de composés à base de lantibiotique de type b à activité antimicrobienne
US7989416B2 (en) 2006-01-17 2011-08-02 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae
US8283371B2 (en) 2009-01-14 2012-10-09 Novacta Biosystems Limited Compounds
US8329644B2 (en) 2007-07-18 2012-12-11 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
US8729031B2 (en) 2009-02-04 2014-05-20 Novacta Biosystems Limited Compounds
US9006392B2 (en) 2010-02-02 2015-04-14 Novacta Biosystems Limited Actagardine derivatives, and pharmaceutical use thereof
US9192569B2 (en) 2010-08-11 2015-11-24 Novacta Biosystems Limited Formulations for infusion of type B lantibiotics
CN107810682A (zh) * 2017-09-28 2018-03-20 江苏省农业科学院 针对小麦纹枯病防治药剂的室内生测方法
CN114457102A (zh) * 2022-02-24 2022-05-10 重庆市畜牧科学院 用于编码分泌型Mersacidin的基因表达盒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700998A1 (fr) * 1994-09-12 1996-03-13 Hoechst Aktiengesellschaft Mersacidine recombinante et méthode de production
WO2005093069A2 (fr) * 2004-03-26 2005-10-06 Novacta Biosystems Limited Production de mersacidine et ses variants dans des cellules hotes negatives de bacillus sigh et/ou mrsa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN167138B (fr) * 1988-08-17 1990-09-01 Hoechst India

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700998A1 (fr) * 1994-09-12 1996-03-13 Hoechst Aktiengesellschaft Mersacidine recombinante et méthode de production
WO2005093069A2 (fr) * 2004-03-26 2005-10-06 Novacta Biosystems Limited Production de mersacidine et ses variants dans des cellules hotes negatives de bacillus sigh et/ou mrsa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SZEKAT C ET AL: "CONSTRUCTION OF AN EXPRESSION SYSTEM FOR SITE-DIRECTED MUTAGENESIS OF THE LANTIBIOTIC MERSACIDIN", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON,DC, US, vol. 69, no. 7, July 2003 (2003-07-01), pages 3777 - 3783, XP001206733, ISSN: 0099-2240 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1794298A2 (fr) * 2004-03-26 2007-06-13 Novacta Biosystems Limited Production de mersacidine et ses variants dans des cellules hotes negatives de bacillus sigh et/ou mrsa
USRE45003E1 (en) 2006-01-17 2014-07-08 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae
US7989416B2 (en) 2006-01-17 2011-08-02 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae
US8465947B2 (en) 2006-01-17 2013-06-18 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae
WO2009010763A1 (fr) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Utilisation de composés à base de lantibiotique de type b à activité antimicrobienne
JP2010533695A (ja) * 2007-07-18 2010-10-28 ノヴァクタ バイオシステムズ リミティッド 抗菌活性を有するｂ型ランチビオティック型化合物の使用
US8329644B2 (en) 2007-07-18 2012-12-11 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
US8575094B2 (en) 2007-07-18 2013-11-05 Novacta Biosystems Limited Use of type-B lantibiotic-based compounds having antimicrobial activity
EA021628B1 (ru) * 2007-07-18 2015-07-30 Новакта Биосистемс Лимитед СОЕДИНЕНИЯ АКТАГАРДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ Clostridium difficile
US8283371B2 (en) 2009-01-14 2012-10-09 Novacta Biosystems Limited Compounds
US8741945B2 (en) 2009-01-14 2014-06-03 Novacta Biosystems Limited Compounds
US8729031B2 (en) 2009-02-04 2014-05-20 Novacta Biosystems Limited Compounds
US9006392B2 (en) 2010-02-02 2015-04-14 Novacta Biosystems Limited Actagardine derivatives, and pharmaceutical use thereof
US9192569B2 (en) 2010-08-11 2015-11-24 Novacta Biosystems Limited Formulations for infusion of type B lantibiotics
CN107810682A (zh) * 2017-09-28 2018-03-20 江苏省农业科学院 针对小麦纹枯病防治药剂的室内生测方法
CN107810682B (zh) * 2017-09-28 2021-08-06 江苏省农业科学院 针对小麦纹枯病防治药剂的室内生测方法
CN114457102A (zh) * 2022-02-24 2022-05-10 重庆市畜牧科学院 用于编码分泌型Mersacidin的基因表达盒及其制备方法
CN114457102B (zh) * 2022-02-24 2023-12-26 重庆市畜牧科学院 用于编码分泌型Mersacidin的基因表达盒及其制备方法

Also Published As

Publication number Publication date
JP2009509519A (ja) 2009-03-12
CA2623624A1 (fr) 2007-04-05
EP1928900A1 (fr) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2007036706A1 (fr) Variantes du lantibiotique mersacidine, et leur utilisation
EP2925772B1 (fr) Nouveau depsipeptide et ses utilisations
JP5613563B2 (ja) 抗菌活性を有するｂ型ランチビオティック型化合物の使用
KR0174264B1 (ko) 약리학적 작용을 갖는 악티노플레인스 종으로부터의 리포펩타이드, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5231013A (en) Polycyclic peptide antibiotic gallidermin
JP5653900B2 (ja) アクチノマデュラ・ナミビエンシス由来の高度に架橋したペプチド
IE80462B1 (en) Purified form of streptogramins its preparation and pharmaceutical compositions containing it
US7592308B2 (en) F3W variants of the lantibiotic mersacidin and its use
CA2646892C (fr) Compose peptidique antimicrobien, sa preparation et ses applications
US20190345199A1 (en) Lipolanthipeptides and their uses as antimicrobial agents
JP3718521B2 (ja) 精製形態のストレプトグラミン類
DK175198B1 (da) Antibioticum, betegnet gallidermin, og syreadditionssalte deraf, farmaceutiske og kosmetiske præparater indeholdende forbindelserne og fremgangsmåde til forbindelsernes fremstilling samt deres anvendelse til fremstilling af et farmaceutisk præparat
IL108641A (en) Cleansed form of strepogrammin, its preparation and pharmaceutical preparations containing it
GB2301821A (en) Purified form of streptogramins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006794575

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008532859

Country of ref document: JP

Ref document number: 2623624

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006794575

Country of ref document: EP